The ARTO trial included 157 patients who had not received prior systemic treatment for metastatic CRPC and had no more than three bone or nodal metastatic lesions (patients with visceral lesions were excluded).

Rezvilutamide significantly delays disease progression and death relative to bicalutamide when each is combined with androgen deprivation therapy in patients with high-volume metastatic, hormone-sensitive prostate cancer, research shows.

Costs related to other diagnostic tests, initial treatment, adverse events, and post-disease progression were included.

Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

Supplementing standard of care treatment with lutetium-177-prostate-specific membrane antigen-617 significantly boosts the outcomes of heavily pretreated men with PSMA-positive metastatic castration-resistant prostate cancer, say the VISION investigators.

The number and location of bone metastases, as determined by conventional imaging, are associated with the survival benefit of prostate radiotherapy in men with newly diagnosed metastatic prostate cancer, STAMPEDE trial data show.

Real-world data suggest that active surveillance may be a feasible treatment option for some patients with metastatic renal cell carcinoma.

To further elucidate the pattern of disease progression after SBRT, the researchers used a “novel metric” of widespread progression (WSP), which they defined as the time to further metastatic dissemination.

The researchers say their findings “provide evidence in support of SABR across a variety of primary tumor histologic characteristics given its excellent [local control] and perhaps more importantly low overall rates of severe acute and late toxic effects, which is particularly important in the context of patients with metastatic disease and limited life expectancies.”

Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.

Cabozantinib has shown promising clinical activity and tolerability in patients with metastatic urothelial carcinoma who have progressed on platinum chemotherapy in a single-center phase 2 trial.

The patient was admitted to the hospital for fever and symptomatic bone metastases pain that was unresponsive to ceftriaxone administered in the outpatient setting.

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

The addition of pembrolizumab to eribulin does not improve the survival outcomes of patients with hormone receptor-positive, HER2-negative metastatic breast cancer, suggests a phase 2 study.

Early data suggest almost a third of patients with metastatic breast cancer could benefit from treatment with the Trop-2-directed antibody–drug conjugate sacituzumab govitecan.

RADICALS-RT trial   The trial recruited 1396 men who underwent radical prostatectomy for nonmetastatic disease at one of 138 centers in Canada, Denmark, Ireland, or the UK, and had a postoperative PSA level no higher than 0.2 ng/mL and at least one of the following risk factors: pathologic T stage 3 or 4; Gleason score of 7–10; positive margins; or preoperative PSA of at least 10 ng/mL.

Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.

Cohort A of KEYNOTE-365 included mCRPC patients who were treated with docetaxel and had PSA or radiologic bone/soft tissue progression within 6 months of screening.

Cytoreductive nephrectomy continues to offer a significant overall survival benefit for carefully selected patients with metastatic renal cell carcinoma in the era of immune checkpoint inhibitor and targeted therapies, a propensity score-based analysis indicates. This independent news story was supported by an educational grant from Pfizer and Merck KGaA